Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>**Q3 FY09/24 Financial Results:** Revenue JPY61mn (+19.3% YoY), operating loss JPY580mn, net loss JPY518mn, total assets JPY2.9bn.</li><li>**Revised FY09/24 Forecast:** Sales JPY79mn, operating loss JPY1.0bn, recurring loss JPY940mn, net loss JPY942mn, net loss per share JPY147.23.</li><li>**Financial Position Changes:** Current assets JPY2.9bn, current liabilities JPY84mn, fixed liabilities JPY517mn, net assets JPY2.3bn, capital stock JPY516mn.</li></ul>

**Q3 FY09/24 Financial Results:** Revenue JPY61mn (+19.3% YoY), operating loss JPY580mn, net loss JPY518mn, total assets JPY2.9bn.**Revised FY09/24 Forecast:** Sales JPY79mn, operating loss JPY1.0bn, recurring loss JPY940mn, net loss JPY942mn, net loss per share JPY147.23.**Financial Position Changes:** Current assets JPY2.9bn, current liabilities JPY84mn, fixed liabilities JPY517mn, net assets JPY2.3bn, capital stock JPY516mn.

Kringle Pharma Inc (4884 JP): Q3 FY09/24 flash update

Japan

Kringle Pharma, Inc. develops and distributes biotechnology products. The Company produces regenerative medicines, cancer therapy medicines, and other products. Kringle Pharma markets its products throughout Japan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kringle Pharma Inc (4884 JP): Q3 FY09/24 flash update

**Q3 FY09/24 Financial Results:** Revenue JPY61mn (+19.3% YoY), operating loss JPY580mn, net loss JPY518mn, total assets JPY2.9bn. **Revised...

Shared Research

Q3 FY09/24 Financial Results: Revenue JPY61mn (+19.3% YoY), operating loss JPY580mn, net loss JPY518mn, total assets JPY2.9bn. **Revised...